Drug Profile
IDX 320
Alternative Names: IDX320Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Idenix Pharmaceuticals
- Class Macrocyclic compounds
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 10 Feb 2011 Idenix has discontinued development of IDX 320
- 10 Feb 2011 Discontinued - Phase-I/II for Hepatitis C in Hungary (PO)
- 10 Feb 2011 Discontinued - Phase-I/II for Hepatitis C in Netherlands (PO)